Clinical Trials Logo

Filter by:
NCT ID: NCT04743687 Recruiting - Clinical trials for Idiopathic Multicentric Castleman's Disease

Zanuburutinib in Relapsed and Refractory iMCD: a Prospective, Single-center, Single-arm Trial

iMCD
Start date: January 1, 2021
Phase: Phase 2
Study type: Interventional

To explore the effectiveness and safety of Zanuburutinib in relapsed and refractory idiopathic Multicentric Castleman's disease (iMCD) patients.

NCT ID: NCT04743479 Recruiting - Diabetes Clinical Trials

Artificial Intelligence-based Early Screening of Pancreatic Cancer and High Risk Tracing (ESPRIT-AI)

ESPRIT-AI
Start date: December 1, 2020
Phase:
Study type: Observational

Pancreatic cancer is one of the most fatal malignancies with a 5-year survival rate of only ~6%[1]. The reasons for this high mortality rate can be attributed to several factors, of which perhaps the most important is delayed diagnosis due to vague symptoms and consequently missed opportunities for surgical resection. Therefore, the ability to detect pancreatic cancer at an early, more curable stage is urgently needed. Identifying risk factors and biomarkers of early pancreatic cancer could facilitate screening for individuals at higher than average risk and expedite the diagnosis in individuals with symptoms and substantially improve an individual's chance of surviving the disease. Thus, the investigators propose this longitudinal study entitled, "Artificial Intelligence-based Early Screening of Pancreatic Cancer and High Risk Tracing (ESPRIT-AI)" in order to generate clinical data sets and bank serial blood specimens of high risk individuals.

NCT ID: NCT04743102 Recruiting - Rectal Cancer Clinical Trials

Multi-points and Full-thickness Biopsy in the Diagnosis of cCR After Neoadjuvant Therapy for Rectal Cancer

BIOPSY
Start date: January 1, 2021
Phase: N/A
Study type: Interventional

Background There is currently no reliable means to restage rectal cancers after neoadjuvant chemoradiation. There are still no reliable methods to identify patients with pCR before radical surgery. As a result, clinical complete response (cCR), defined as no clinical detectable tumor by physical examination, endoscopic evaluation, and imaging, is designed as a surrogate endpoint for pCR. However, the concordance between cCR and pCR varies from 22% to 96% in different reports, which questions the clinical value of such strategies. Therefore, based on rectal diginal examination, serum CEA, MRI, endoscopy examination, we suggested to add multi-points and full-thickness biopsy technique to further improve the accuracy of cCR.

NCT ID: NCT04742153 Recruiting - Clinical trials for Advanced or Metastatic Breast Cancer

A Study of MRG002 in the Treatment of Patients With HER2-low Locally Advanced or Metastatic Breast Cancer (BC)

Start date: May 13, 2021
Phase: Phase 2
Study type: Interventional

The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG002 in patients with HER2-low locally advanced or metastatic BC.

NCT ID: NCT04742114 Recruiting - Emphysema Clinical Trials

Effect of EPAP Device on Emphysema and Lung Bullae

Start date: July 31, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the safety and the effects and of the application of Expiratory Positive Airway Pressure (EPAP) device on Dynamic Hyperinflation and dyspnea in patients with Emphysema and pulmonary bullae.

NCT ID: NCT04741633 Recruiting - NSCLC Clinical Trials

Multi Dimensional Precise Exploration of Immunoconsolidation Therapy for Locally Advanced NSCLC After Chemo-radiotherapy

NSCLC
Start date: April 1, 2020
Phase:
Study type: Observational

The purpose of this study is to carry out a prospective observational study in patients with locally advanced NSCLC receiving radical concurrent chemoradiotherapy and follow-up immune consolidation therapy. By detecting ctDNA and TILs of the patients, we explored the value of blood dynamic monitoring of ctDNA in patients with prognosis stratification and treatment effect, and explored the patients before and after concurrent chemoradiotherapy and immune consolidation therapy The characteristics of DNA, RNA, T cells and other biomarkers were correlated with the efficacy and prognosis.

NCT ID: NCT04741490 Recruiting - Clinical trials for Esophageal Squamous Cell Carcinomas

Camrelizumab Combined With Radiotherapy for Adjuvant Treatment of Esophageal Squamous Cell Carcinoma After Surgery

Start date: February 2021
Phase: N/A
Study type: Interventional

This is an investigator-initiated, single-arm, single-center, exploratory clinical study.The study population consisted of patients with R0 resection of esophageal squamous cell carcinoma who had not received radiation therapy.The purpose of this study was to evaluate the efficacy and safety of carrelizumab combined with radiotherapy in the adjuvant treatment of esophageal squamous cell carcinoma after surgery.About 20 subjects are planned to be enrolled in this study.Drug regimen: Patients with esophageal squamous cell carcinoma received radiotherapy combined with carrilizumab adjuvant therapy for 6 cycles 1-3 months after R0 resection.

NCT ID: NCT04741373 Recruiting - Body Composition Clinical Trials

Study on Pulmonary Rehabilitation for Stable Chronic Obstructive Pulmonary Disease(COPD) Patients

Start date: April 1, 2021
Phase: N/A
Study type: Interventional

To compare the difference of effectiveness for stable COPD patients with poor nutritional status among three groups named health education, upper and lower limb exercises, and oral nutritional supplements. Then formulate the best pulmonary rehabilitation guidance strategy according to the result of this trial.

NCT ID: NCT04741308 Recruiting - Colorectal Cancer Clinical Trials

Cognitive Behavior Therapy (CBT) and Psychological Status and Immune Function

Start date: March 1, 2021
Phase: N/A
Study type: Interventional

To explore the effect of CBT on psychological status of colorectal cancer patients undergoing chemotherapy. To explore the effect of CBT on immune function of colorectal cancer patients undergoing chemotherapy.

NCT ID: NCT04741165 Recruiting - Clinical trials for Hepatocellular Carcinoma

Study of HX008 in Combination With Bevacizumab or Lenvatinib for the Treatment of Advanced Hepatocellular Carcinoma (HCC)

Start date: January 7, 2021
Phase: Phase 2
Study type: Interventional

This is a multi-center,open-label study to evaluate the efficacy and safety of anti-PD-1 antibody HX008 plus bevacizumab or lenvatinib in the first-line treatment of patients with unresectable hepatocellular carcinoma.